TGFB1 and systemic sclerosis: In systemic sclerosis, IL-27-MSC likely suppress TGF-β signaling through TSG-6, reducing collagen deposition and cutaneous fibrosis while improving vascular dysfunction and Raynaud’s phenomenon [59].